Teresa Parli

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · European Urology · 2016 · 419 citations · Full text

Medicine, Oncology, Pharmacology +13

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

Andrew J. Armstrong, Ping Lin, Bertrand Tombal et al. · European Urology · 2020 · 163 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL

Julie N. Graff, G. Baciarello, Andrew J. Armstrong et al. · Annals of Oncology · 2015 · 117 citations · Full text

Medicine, Oncology, Pharmacology +14

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

Deepak L. Bhatt, Harold Bays, Michael Miller et al. · Nature Medicine · 2023 · 101 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer

Dana E. Rathkopf, Tomasz M. Beer, Yohann Loriot et al. · JAMA Oncology · 2018 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17